The market share for generics, which is already 54 percent [of prescriptions] should increase significantly,

We continue to believe that NRP104 has a best-in-class clinical profile and blockbuster market potential, given its improved safety profile compared to other stimulants.

a million and one different vendors. Unless they test everyone, the findings are meaningless.

For the remaining players it's going to be tough. It's tough already.

The psychology of it -- $100 -- it seems like a lot. That's a nice problem to have. So few companies are doing very, very well.

You're talking about very rapid adoption.